Literature DB >> 28715578

Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.

Hiten D Patel1,2, Jeffrey J Tosoian1,2, H Ballentine Carter1,2, Jonathan I Epstein1,2,3.   

Abstract

IMPORTANCE: Active surveillance is recommended for patients with very low-risk (VLR) and low-risk (LR) prostate cancer. Despite controversy, recent clinical guidelines state surveillance may be considered for men with low-volume intermediate-risk (LVIR) disease.
OBJECTIVE: To compare rates of adverse pathologic findings among VLR, LR, and LVIR men electing immediate radical prostatectomy and evaluate criteria to define if a favorable intermediate-risk group minimizing risk exists. DESIGN, SETTING, AND PARTICIPANTS: This was a cohort study of men (2005-July 2016) with clinically localized VLR (1264 patients), LR (4849 patients), and LVIR (608 patients) (1-2 cores, Gleason 3 + 4 = 7, prostate-specific antigen [PSA] level <20 ng/mL) prostate cancer undergoing radical prostatectomy evaluated retrospectively at Johns Hopkins Hospital.
INTERVENTIONS: Radical prostatectomy. MAIN OUTCOMES AND MEASURES: The proportions of men found to have at least Gleason 4 + 3 = 7 disease and other adverse pathologic features were compared by risk group. Log-binomial regression calculated relative risk (RR) of adverse pathologic findings in the LVIR cohort compared with VLR and LR cohorts. Analyses were repeated in subgroups of the LVIR population who otherwise met criteria for VLR (T1c, PSA density [PSAD] <0.15 ng/mL/cm3, ≤50% cancer in any core) and LR (≤T2a, PSA level <10 ng/mL) disease. Rates of adverse pathologic findings within the LVIR group were calculated based on various clinical thresholds, and univariable and multivariable logistic regression analyses were performed to identify predictors of adverse pathologic findings.
RESULTS: The rate of adverse pathologic findings was significantly higher for LVIR disease (150 of 608 patients [24.7%]; RR, 4.50; 95% CI, 3.73-5.43; P < .001) compared with LR disease (280 of 4849 [5.8%]), and LVIR disease (RR, 5.14; 95% CI, 3.84-6.89; P < .001) compared with men with VLR disease (60 of 1264 [4.7%]). Restriction of LVIR men to additional criteria did not significantly affect results. There were no preoperative clinical or pathologic criteria that could identify a subgroup of the LVIR population with rates of adverse pathologic findings comparable with those of the VLR and LR cohorts. PSAD was a significant predictor of adverse pathologic findings, but Gleason score had the largest effect (odds ratio, 4.30 (95% CI, 3.40-5.44; P < .001). CONCLUSIONS AND RELEVANCE: Nearly 25% of men (150 of 608) electing immediate radical prostatectomy with low-volume, Gleason 3 + 4 prostate cancer on biopsy are found to harbor adverse surgical pathologic findings. These data do not support the presence of a "favorable" subgroup among included patients and could have important implications for active surveillance in similar patients with Gleason 3 + 4 = 7 prostate cancer.

Entities:  

Mesh:

Year:  2018        PMID: 28715578      PMCID: PMC5833628          DOI: 10.1001/jamaoncol.2017.1879

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  15 in total

1.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

2.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

3.  Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Authors:  Ann C Raldow; Danjie Zhang; Ming-Hui Chen; Michelle H Braccioforte; Brian J Moran; Anthony V D'Amico
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

4.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Isaac Pei; Zhigang Zhang; Yoshiya Yamada; Marisa Kollmeier; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-03-23       Impact factor: 20.096

5.  Active surveillance for prostate cancer: patient selection and management.

Authors:  L Klotz
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 6.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

7.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

8.  Radical prostatectomy or watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

9.  Practice patterns and individual variability of surgeons performing radical prostatectomy at a high volume academic center.

Authors:  Hiten D Patel; Elizabeth Humphreys; Bruce J Trock; Misop Han; H Ballentine Carter
Journal:  J Urol       Date:  2014-09-06       Impact factor: 7.450

10.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Authors:  Jonathan I Epstein; Michael J Zelefsky; Daniel D Sjoberg; Joel B Nelson; Lars Egevad; Cristina Magi-Galluzzi; Andrew J Vickers; Anil V Parwani; Victor E Reuter; Samson W Fine; James A Eastham; Peter Wiklund; Misop Han; Chandana A Reddy; Jay P Ciezki; Tommy Nyberg; Eric A Klein
Journal:  Eur Urol       Date:  2015-07-10       Impact factor: 20.096

View more
  11 in total

Review 1.  Advances in the selection of patients with prostate cancer for active surveillance.

Authors:  James L Liu; Hiten D Patel; Nora M Haney; Jonathan I Epstein; Alan W Partin
Journal:  Nat Rev Urol       Date:  2021-02-23       Impact factor: 14.432

Review 2.  A review on the role of tissue-based molecular biomarkers for active surveillance.

Authors:  Sanoj Punnen
Journal:  World J Urol       Date:  2021-02-15       Impact factor: 4.226

3.  Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.

Authors:  Sanoj Punnen; Radka Stoyanova; Deukwoo Kwon; Isildinha M Reis; Nachiketh Soodana-Prakash; Chad R Ritch; Bruno Nahar; Mark L Gonzalgo; Bruce Kava; Yang Liu; Himanshu Arora; Sandra M Gaston; Rosa P Castillo Acosta; Alan Dal Pra; Matthew Abramowitz; Oleksandr N Kryvenko; Elai Davicioni; Alan Pollack; Dipen J Parekh
Journal:  J Urol       Date:  2020-12-24       Impact factor: 7.450

4.  Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?

Authors:  Duc Minh Pham; Jung Kwon Kim; Sangchul Lee; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Investig Clin Urol       Date:  2020-05-25

5.  The Impact of the Ongoing COVID-19 Epidemic on the Increasing Risk of Adverse Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy.

Authors:  Łukasz Nyk; Hubert Kamecki; Bartłomiej Zagożdżon; Andrzej Tokarczyk; Piotr Baranek; Łukasz Mielczarek; Piotr Kryst; Sławomir Poletajew; Roman Sosnowski; Stanisław Szempliński
Journal:  Curr Oncol       Date:  2022-04-15       Impact factor: 3.109

6.  Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.

Authors:  Gabriele Sorce; Rocco Simone Flammia; Benedikt Hoeh; Francesco Chierigo; Lukas Hohenhorst; Andrea Panunzio; Armando Stabile; Giorgio Gandaglia; Zhe Tian; Derya Tilki; Carlo Terrone; Michele Gallucci; Felix K H Chun; Alessandro Antonelli; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz
Journal:  Prostate       Date:  2022-04-01       Impact factor: 4.012

Review 7.  Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.

Authors:  Leandro Blas; Masaki Shiota; Masatoshi Eto
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

8.  Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?

Authors:  T Stonier; A L Tin; D D Sjoberg; G Jibara; A J Vickers; S Fine; J Eastham
Journal:  J Urol       Date:  2020-11-20       Impact factor: 7.450

Review 9.  Targeted Prostate Biopsy in the Era of Active Surveillance.

Authors:  Fuad F Elkhoury; Demetrios N Simopoulos; Leonard S Marks
Journal:  Urology       Date:  2017-09-27       Impact factor: 2.633

Review 10.  Entering an era of radiogenomics in prostate cancer risk stratification.

Authors:  Nachiketh Soodana-Prakash; Radka Stoyanova; Abhishek Bhat; Maria C Velasquez; Omer E Kineish; Alan Pollack; Dipen J Parekh; Sanoj Punnen
Journal:  Transl Androl Urol       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.